The DOI matches its Crossref record; 78 of the 78 references it cites were found in a registry or an index.
Disease‐modifying treatments for multiple sclerosis – a review of approved medications
Open accessAbstract
Background and purpose: There is still no curative treatment for multiple sclerosis (MS), but during the last 20 years eight different disease‐modifying compounds have been approved for relapsing−remitting MS(RRMS). Methods: A literature search was conducted on published randomized controlled phase III trials indexed in PubMed on the approved medications until 21 May 2015. Results: In this review the mode of action, documented treatment effects and side effects of the approved MS therapies are briefly discussed. Conclusions: Based on current knowledge of risk−benefit of the approved MS medications, including factors influencing adherence, it is suggested that oral treatment with dimethyl fumarate or teriflunomide should be preferred as a starting therapy amongst the first‐line preparations for de novoRRMS. In the case of breakthrough disease on first‐line therapy, or rapidly evolving severe RRMS, second‐line therapy with natalizumab, fingolimod or alemtuzumab should be chosen based on careful risk−benefit stratification.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Axonal transection in the lesions of multiple sclerosis
Trapp, B. D., Peterson, J., Ransohoff, R. M., Rudick, R., Mörk, S., & Bö, L. (1998) · New England Journal of Medicine · doi:10.1056/nejm199801293380502 · Cited by 4,029
Self-citationA Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis
Polman, C. H., O'Connor, P. W., Havrdova, E., Hutchinson, M., Kappos, L., Miller, D. H., Phillips, J. T., Lublin, F. D., Giovannoni, G., Wajgt, A., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa044397 · Cited by 3,386
A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis
Kappos, L., Radue, E.-W., O'Connor, P., Polman, C., Hohlfeld, R., Calabresi, P., Selmaj, K., Agoropoulou, C., Leyk, M., Zhang-Auberson, L., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0909494 · Cited by 2,644
Intramuscular interferon beta‐1a for disease progression in relapsing multiple sclerosis
Jacobs, L. D., Cookfair, D. L., Rudick, R. A., Herndon, R. M., Richert, J. R., Salazar, A. M., Fischer, J. S., Goodkin, D. E., Granger, C. V., Simon, J. H., et al. (1996) · Annals of Neurology · doi:10.1002/ana.410390304 · Cited by 2,450
B-cell depletion with rituximab in relapsing-remitting multiple sclerosis
Hauser, S. L., Waubant, E., Arnold, D. L., Vollmer, T., Antel, J., Fox, R. J., Bar-Or, A., Panzara, M., Sarkar, N., Agarwal, S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0706383 · Cited by 2,439
Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis
Cohen, J. A., Barkhof, F., Comi, G., Hartung, H.-P., Khatri, B. O., Montalban, X., Pelletier, J., Capra, R., Gallo, P., Izquierdo, G., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907839 · Cited by 2,204
The IFNB Multiple Sclerosis Study Group (1993) · Neurology · doi:10.1212/wnl.43.4.655 · Cited by 2,085
Ebers, G. C. (1998) · The Lancet · doi:10.1016/s0140-6736(98)03334-0 · Cited by 2,073
Johnson, K. P., Brooks, B. R., Cohen, J. A., Ford, C. C., Goldstein, J., Lisak, R. P., Myers, L. W., Panitch, H. S., Rose, J. W., Schiffer, R. B., et al. (1995) · Neurology · doi:10.1212/wnl.45.7.1268 · Cited by 1,898
Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis
Gold, R., Kappos, L., Arnold, D. L., Bar-Or, A., Giovannoni, G., Selmaj, K., Tornatore, C., Sweetser, M. T., Yang, M., Sheikh, S. I., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1114287 · Cited by 1,733
Jacobs, L. D., Beck, R. W., Simon, J. H., Kinkel, R. P., Brownscheidle, C. M., Murray, T. J., Simonian, N. A., Slasor, P. J., & Sandrock, A. W. (2000) · New England Journal of Medicine · doi:10.1056/nejm200009283431301 · Cited by 1,501
Placebo-Controlled Phase 3 Study of Oral BG-12 or Glatiramer in Multiple Sclerosis
Fox, R. J., Miller, D. H., Phillips, J. T., Hutchinson, M., Havrdova, E., Kita, M., Yang, M., Raghupathi, K., Novas, M., Sweetser, M. T., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1206328 · Cited by 1,355
Natalizumab plus Interferon Beta-1a for Relapsing Multiple Sclerosis
Rudick, R. A., Stuart, W. H., Calabresi, P. A., Confavreux, C., Galetta, S. L., Radue, E.-W., Lublin, F. D., Weinstock-Guttman, B., Wynn, D. R., Lynn, F., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa044396 · Cited by 1,344
Risk of Natalizumab-Associated Progressive Multifocal Leukoencephalopathy
Bloomgren, G., Richman, S., Hotermans, C., Subramanyam, M., Goelz, S., Natarajan, A., Lee, S., Plavina, T., Scanlon, J. V., Sandrock, A., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1107829 · Cited by 1,242
Cohen, J. A., Coles, A. J., Arnold, D. L., Confavreux, C., Fox, E. J., Hartung, H.-P., Havrdova, E., Selmaj, K. W., Weiner, H. L., Fisher, E., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61769-3 · Cited by 1,205
Coles, A. J., Twyman, C. L., Arnold, D. L., Cohen, J. A., Confavreux, C., Fox, E. J., Hartung, H.-P., Havrdova, E., Selmaj, K. W., Weiner, H. L., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61768-1 · Cited by 1,198
Girard, M., Duquette, P., & Sibley, W. A. (1993) · Cited by 1,196
Comi, G., Filippi, M., Barkhof, F., Durelli, L., Edan, G., Fernández, O., Hartung, H.-P., Seeldrayers, P., Sørensen, P. S., Rovaris, M., et al. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04725-5 · Cited by 1,053
Multiple Sclerosis: Current Knowledge and Future Outlook
Kamm, C. P., Uitdehaag, B. M., & Polman, C. H. (2014) · European Neurology · doi:10.1159/000360528 · Cited by 1,010
Randomized Trial of Oral Teriflunomide for Relapsing Multiple Sclerosis
O'Connor, P., Wolinsky, J. S., Confavreux, C., Comi, G., Kappos, L., Olsson, T. P., Benzerdjeb, H., Truffinet, P., Wang, L., Miller, A., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1014656 · Cited by 990
Hartung, H.-P., Gonsette, R., Konig, N., Kwiecinski, H., Guseo, A., Morrissey, S. P., Krapf, H., & Zwingers, T. (2002) · The Lancet · doi:10.1016/s0140-6736(02)12023-x · Cited by 946
Kappos, L. (1998) · The Lancet · doi:10.1016/s0140-6736(98)10039-9 · Cited by 936
Calabresi, P. A., Radue, E.-W., Goodin, D., Jeffery, D., Rammohan, K. W., Reder, A. T., Vollmer, T., Agius, M. A., Kappos, L., Stites, T., et al. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70049-3 · Cited by 825
Comi, G., Filippi, M., & Wolinsky, J. S. (2001) · PubMed · Cited by 688
Kappos, L., Polman, C. H., Freedman, M. S., Edan, G., Hartung, H. P., Miller, D. H., Montalban, X., Barkhof, F., Bauer, L., Jakobs, P., et al. (2006) · Neurology · doi:10.1212/01.wnl.0000237641.33768.8d · Cited by 681
Comi, G., Filippi, M., Wolinsky, J. S., & European/Canadian Glatiramer Acetate Study Group (2001) · Annals of Neurology · doi:10.1002/ana.64 · Cited by 650
Clifford, D. B., DeLuca, A., Simpson, D. M., Arendt, G., Giovannoni, G., & Nath, A. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70028-4 · Cited by 636
Randomized, comparative study of interferon β-1a treatment regimens in MS: The EVIDENCE Trial
Panitch, H., Goodin, D. S., Francis, G., Chang, P., Coyle, P. K., O’Connor, P., Monaghan, E., Li, D., & Weinshenker, B. (2002) · Neurology · doi:10.1212/01.wnl.0000034080.43681.da · Cited by 635
Comi, G., Martinelli, V, Rodegher, M., Moiola, L., Bajenaru, O., Carra, A., Elovaara, I., Fazekas, F., Hartung, H., Hillert, J., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61259-9 · Cited by 592
Self-citationConfavreux, C., O'Connor, P., Comi, G., Freedman, M. S., Miller, A. E., Olsson, T. P., Wolinsky, J. S., Bagulho, T., Delhay, J.-L., Dukovic, D., et al. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70308-9 · Cited by 579
PRISMS-4: Long-term efficacy of interferon-β-1a in relapsing MS
The PRISMS (Prevention of Relapses and Disability by Interferon-β-1a Subcutaneously in Multiple Sclerosis) Study Group, & the University of British Columbia MS/MRI Analysis Group (2001) · Neurology · doi:10.1212/wnl.56.12.1628 · Cited by 571
Kappos, L., Polman, C. H., Freedman, M. S., Edan, G., Hartung, H. P., Miller, D. H., Montalban, X., Barkhof, F., Bauer, L., Jakobs, P., et al. (2007) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2006.11.003 · Cited by 549
Durelli, L., Verdun, E., Barbero, P., Bergui, M., Versino, E., Ghezzi, A., Montanari, E., & Zaffaroni, M. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08430-1 · Cited by 547
Coles, A. J., Cox, A., Page, E., Jones, J., Trip, S. A., Deans, J., Seaman, S., Miller, D. H., Hale, G., Waldmann, H., et al. (2006) · Journal of Neurology · doi:10.1007/s00415-005-0934-5 · Cited by 506
Mikol, D. D., Barkhof, F., Chang, P., Coyle, P. K., Jeffery, D. R., Schwid, S. R., Stubinski, B., & Uitdehaag, B. M. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70200-x · Cited by 486
Randomized controlled trial of interferon- beta-1a in secondary progressive MS: Clinical results
Secondary Progressive Efficacy Clinical Trial of Recombinant Interferon-beta-1a in MS (SPECTRIMS) Study Group* (2001) · Neurology · doi:10.1212/wnl.56.11.1496 · Cited by 475
PRISMS-4: Long-term efficacy of interferon-beta-1a in relapsing MS
Francis, G., Hughes, R. A., King, J. O., Mitchell, P. I., Joubert, J.-M., McLeod, J., Parker, G., Pollard, J. D., Sindic, C., Duprez, T. P. J., et al. (2001) · DIAL (Catholic University of Leuven) · doi:10.25405/ncl.34089345 · Cited by 472
Randomized controlled trial of interferon-beta-1a in secondary progressive MS: MRI results
Li, D. K. B., Zhao, G. J., Paty, D. W., & the University of British Columbia MS/MRI Analysis Research Group and the SPECTRIMS Study Group* (2001) · Neurology · doi:10.1212/wnl.56.11.1505 · Cited by 458
Plavina, T., Subramanyam, M., Bloomgren, G., Richman, S., Pace, A., Lee, S., Schlain, B., Campagnolo, D., Belachew, S., & Ticho, B. (2014) · Annals of Neurology · doi:10.1002/ana.24286 · Cited by 438
Wolinsky, J. S., Narayana, P. A., O'Connor, P., Coyle, P. K., Ford, C., Johnson, K., Miller, A., Pardo, L., Kadosh, S., Ladkani, D., et al. (2007) · Annals of Neurology · doi:10.1002/ana.21079 · Cited by 429
Interferon beta-1b in secondary progressive MS: Results from a 3-year controlled study
The North American Study Group on Interferon beta-1b in Secondary Progressive MS (2004) · Neurology · doi:10.1212/01.wnl.0000146958.77317.3e · Cited by 423
O'Connor, P., Filippi, M., Arnason, B., Comi, G., Cook, S., Goodin, D., Hartung, H.-P., Jeffery, D., Kappos, L., Boateng, F., et al. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70226-1 · Cited by 405
Benefit of interferon β-1a on MSFC progression in secondary progressive MS
Cohen, J. A., Cutter, G. R., Fischer, J. S., Goodman, A. D., Heidenreich, F. R., Kooijmans, M. F., Sandrock, A. W., Rudick, R. A., Simon, J. H., Simonian, N. A., et al. (2002) · Neurology · doi:10.1212/wnl.59.5.679 · Cited by 402
Calabresi, P. A., Kieseier, B. C., Arnold, D. L., Balcer, L. J., Boyko, A., Pelletier, J., Liu, S., Zhu, Y., Seddighzadeh, A., Hung, S., et al. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70068-7 · Cited by 398
Vermersch, P., Czlonkowska, A., Grimaldi, L. M., Confavreux, C., Comi, G., Kappos, L., Olsson, T. P., Benamor, M., Bauer, D., Truffinet, P., et al. (2014) · Multiple Sclerosis Journal · doi:10.1177/1352458513507821 · Cited by 354
Miller, A. E., Wolinsky, J. S., Kappos, L., Comi, G., Freedman, M. S., Olsson, T. P., Bauer, D., Benamor, M., Truffinet, P., & O'Connor, P. W. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70191-7 · Cited by 300
Interferon-β mechanisms of action in multiple sclerosis
Dhib-Jalbut, S., & Marks, S. (2010) · Neurology · doi:10.1212/wnl.0b013e3181c97d99 · Cited by 298
Safety and efficacy of ofatumumab in relapsing-remitting multiple sclerosis: A phase 2 study
Sorensen, P. S., Lisby, S., Grove, R., Derosier, F., Shackelford, S., Havrdova, E., Drulovic, J., & Filippi, M. (2014) · Neurology · doi:10.1212/wnl.0000000000000125 · Cited by 278
Millefiorini, E., Gasperini, C., Pozzilli, C., D'Andrea, F., Bozzao, A., Calo', A., Bernini, M. L., Gambi, D., Prencipe, M., Bastianello, S., et al. (1997) · Journal of Neurology · doi:10.1007/s004150050066 · Cited by 269
Scoring treatment response in patients with relapsing multiple sclerosis
Sormani, M., Rio, J., Tintorè, M., Signori, A., Li, D., Cornelisse, P., Stubinski, B., Stromillo, M., Montalban, X., & De Stefano, N. (2013) · Multiple Sclerosis Journal · doi:10.1177/1352458512460605 · Cited by 262
Interferon β-1a in primary progressive MS: An exploratory, randomized, controlled trial
Leary, S. M., Miller, D. H., Stevenson, V. L., Brex, P. A., Chard, D. T., & Thompson, A. J. (2003) · Neurology · doi:10.1212/wnl.60.1.44 · Cited by 251
Alemtuzumab treatment of multiple sclerosis: long-term safety and efficacy
Tuohy, O., Costelloe, L., Hill-Cawthorne, G., Bjornson, I., Harding, K., Robertson, N., May, K., Button, T., Azzopardi, L., Kousin-Ezewu, O., et al. (2015) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2014-307721 · Cited by 238
Sørensen, P. S., Deisenhammer, F., Duda, P., Hohlfeld, R., Myhr, K. ‐., Palace, J., Polman, C., Pozzilli, C., Ross, C., & for the EFNS Task Force on Anti‐IFN‐β Antibodies in Multiple Sclerosis (2005) · European Journal of Neurology · doi:10.1111/j.1468-1331.2005.01386.x · Cited by 226
Self-citationPaolillo, A., Coles, A. J., Molyneux, P. D., Gawne–Cain, M., MacManus, D., Barker, G. J., Compston, D. A. S., & Miller, D. H. (1999) · Neurology · doi:10.1212/wnl.53.4.751 · Cited by 220
Comi, G., De Stefano, N., Freedman, M. S., Barkhof, F., Polman, C. H., Uitdehaag, B. M., Casset-Semanaz, F., Hennessy, B., Moraga, M. S., Rocak, S., et al. (2012) · The Lancet Neurology · doi:10.1016/s1474-4422(11)70262-9 · Cited by 220
PML in a Patient with Lymphocytopenia Treated with Dimethyl Fumarate
Rosenkranz, T., Novas, M., & Terborg, C. (2015) · New England Journal of Medicine · doi:10.1056/nejmc1415408 · Cited by 188
Predictors of long‐term outcome in multiple sclerosis patients treated with interferon beta
Bermel, R. A., You, X., Foulds, P., Hyde, R., Simon, J. H., Fisher, E., & Rudick, R. A. (2013) · Annals of Neurology · doi:10.1002/ana.23758 · Cited by 180
Multiple sclerosis: Prospects and promise
Hauser, S. L., Chan, J. R., & Oksenberg, J. R. (2013) · Annals of Neurology · doi:10.1002/ana.24009 · Cited by 179
Burman, J., Iacobaeus, E., Svenningsson, A., Lycke, J., Gunnarsson, M., Nilsson, P., Vrethem, M., Fredrikson, S., Martin, C., Sandstedt, A., et al. (2014) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2013-307207 · Cited by 166
Linker, R. A., & Gold, R. (2013) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-013-0394-8 · Cited by 154
AXONAL TRANSECTION IN THE LESIONS OF MULTIPLE SCLEROSIS
Rapp, D., Eterson, J. O. P., Ansohoff, R. I. M. R., Udick, R. I. R., & Örk, S. V. M. (1998) · Cited by 141
Freedom from disease activity in multiple sclerosis
Havrdová, E., Galetta, S. L., Stefoski, D., & Comı, G. (2010) · Neurology · doi:10.1212/wnl.0b013e3181dbb51c · Cited by 140
The mechanism of action of glatiramer acetate treatment in multiple sclerosis
Racke, M. K., Lovett‐Racke, A. E., & Karandikar, N. J. (2009) · Neurology · doi:10.1212/wnl.0b013e3181c97e39 · Cited by 134
Koch, M. W., Mostert, J. P., de Vries, J. J., & Keyser, J. D. (2007) · Neurology · doi:10.1212/01.wnl.0000261131.23708.1c · Cited by 128
Río, J., Rovira, À., Tintoré, M., Huerga, E. C., Nos, C., Téllez, N., Tur, C., Comabella, M., & Montalbán, X. (2008) · Multiple Sclerosis Journal · doi:10.1177/1352458507085555 · Cited by 115
Manufacturer's Response to Case Reports of PML
Sweetser, M. T., Dawson, K. T., & Bozic, C. M. (2013) · New England Journal of Medicine · doi:10.1056/nejmc1300283 · Cited by 99
Amato, M. P., & Portaccio, E. (2015) · CNS Drugs · doi:10.1007/s40263-015-0238-y · Cited by 93
Edan, G., Comı, G., Page, E. L., Leray, E., Rocca, M. A., Filippi, M., & for The French-Italian Mitoxantrone Interferon-beta-1b Trial Group (2011) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.2010.229724 · Cited by 93
Hematopoietic Stem Cell Therapy for Multiple Sclerosis: Top 10 Lessons Learned
Atkins, H. L., & Freedman, M. S. (2012) · Neurotherapeutics · doi:10.1007/s13311-012-0162-5 · Cited by 78
Acute myeloid leukemia in Italian patients with multiple sclerosis treated with mitoxantrone
Martinelli, V., Cocco, E. E., Capra, R., Salemi, G., Gallo, P., Capobianco, M. A. N., Pesci, I., Ghezzi, A., Pozzilli, C., Lugaresi, A., et al. (2011) · Neurology · doi:10.1212/wnl.0b013e318238ee00 · Cited by 71
Assessment of cancer risk with β-interferon treatment for multiple sclerosis
Kingwell, E., Evans, C. D., Zhu, F., Oger, J., Hashimoto, S. A., & Tremlett, H. L. (2014) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2013-307238 · Cited by 47
Induction Therapy for Patients with Multiple Sclerosis: Why? When? How?
Edan, G., & Page, E. L. (2013) · CNS Drugs · doi:10.1007/s40263-013-0065-y · Cited by 41
Alemtuzumab: evidence for its potential in relapsing–remitting multiple sclerosis
Brown, J. W. L., & Coles, A. J. (2013) · Drug Design Development and Therapy · doi:10.2147/dddt.s32687 · Cited by 32
Ellis, R. E., Brown, S., & Boggild, M. (2014) · Multiple Sclerosis Journal · doi:10.1177/1352458514541508 · Cited by 29
Teriflunomide for oral therapy in multiple sclerosis
Papadopoulou, A., Kappos, L., & Sprenger, T. (2012) · Expert Review of Clinical Pharmacology · doi:10.1586/ecp.12.56 · Cited by 28
Kordower (1999) · doi:10.1002/1531-8249(199909)46:3
Cited by
Inflammation in CNS neurodegenerative diseases
Stephenson, J., Nutma, E., van der Valk, P., & Amor, S. (2018) · Immunology · doi:10.1111/imm.12922 · Cited by 966
Tryptophan metabolism and gut-brain homeostasis
Roth, W., Zadeh, K., Vekariya, R., Ge, Y., & Mohamadzadeh, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22062973 · Cited by 519
Progressive multiple sclerosis: from pathophysiology to therapeutic strategies
Faissner, S., Plemel, J. R., Gold, R., & Yong, V. W. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0035-2 · Cited by 459
Survival and cause of death in multiple sclerosis: a 60-year longitudinal population study
Lunde, H. M. B., Assmus, J., Myhr, K.-M., Bø, L., & Grytten, N. (2017) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2016-315238 · Cited by 269
Self-citationPiket, E., Zheleznyakova, G. Y., Kular, L., & Jagodic, M. (2019) · Journal of Autoimmunity · doi:10.1016/j.jaut.2019.04.002 · Cited by 79
Metadata
- Authors
- Torkildsen, Ø., Myhr, K. ‐., & Bø, L.
- Venue
- European Journal of Neurology
- Publisher
- Wiley
- Published
- 2015-11-13
- Volume
- 23
- Issue
- S1
- Pages
- 18-27
- ISSN
- 1351-5101 (ISSN-L)
- 1468-1331
- OpenAlex
- W2179093540
- Cited by
- 280
- References
- 78
- FWCI
- 20.65
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.